{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:22:10Z","timestamp":1790709730900,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.cellimm.2016.06.004","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T14:26:54Z","timestamp":1467383214000},"page":"32-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis"],"prefix":"10.1016","volume":"309","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-3589","authenticated-orcid":false,"given":"Ifeoma","family":"Okwor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude E.","family":"Uzonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2016.06.004_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2016.06.004_b0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.det.2015.03.018","article-title":"New world and old world Leishmania infections: a practical review","volume":"33","author":"Kevric","year":"2015","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.cellimm.2016.06.004_b0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tmaid.2011.07.001","article-title":"Cutaneous leishmaniasis in British troops following jungle training in Belize","volume":"9","author":"Bailey","year":"2011","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.cellimm.2016.06.004_b0020","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4269\/ajtmh.2008.79.843","article-title":"Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis","volume":"79","author":"Hartzell","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.cellimm.2016.06.004_b0025","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaad.2005.01.109","article-title":"Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options","volume":"52","author":"Willard","year":"2005","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001463","article-title":"Genetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from Afghanistan","volume":"6","author":"Plourde","year":"2012","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.cellimm.2016.06.004_b0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1155\/2008\/802710","article-title":"Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan","volume":"19","author":"Keynan","year":"2008","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0040","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2007.11.008","article-title":"Cutaneous leishmaniasis in Texas: a northern spread of endemic areas","volume":"58","author":"Wright","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2012.00128","article-title":"Protective immunity and vaccination against cutaneous leishmaniasis","volume":"3","author":"Okwor","year":"2012","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.det.2010.08.014","article-title":"Innate immunity and Leishmania vaccination strategies","volume":"29","author":"Birnbaum","year":"2011","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.cellimm.2016.06.004_b0055","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.4049\/jimmunol.154.10.5320","article-title":"IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis","volume":"154","author":"Scharton-Kersten","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0060","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4049\/jimmunol.155.2.730","article-title":"Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice","volume":"155","author":"Heinzel","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0065","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.177.6.1797","article-title":"Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response","volume":"177","author":"Sypek","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2016.06.004_b0070","doi-asserted-by":"crossref","first-page":"896","DOI":"10.4049\/jimmunol.165.2.896","article-title":"IL-12 is required to maintain a Th1 response during Leishmania major infection","volume":"165","author":"Park","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0075","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/1521-4141(200007)30:7<2007::AID-IMMU2007>3.0.CO;2-W","article-title":"Maintenance of IL-12-responsive CD4+ T cells during a Th2 response in Leishmania major-infected mice","volume":"30","author":"Hondowicz","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.cellimm.2016.06.004_b0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/IAI.69.1.245-251.2001","article-title":"Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection","volume":"69","author":"Gicheru","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cellimm.2016.06.004_b0090","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.168.11.5771","article-title":"The role of IL-12 in maintaining resistance to Leishmania major","volume":"168","author":"Park","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0095","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.4049\/jimmunol.180.9.6139","article-title":"Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis","volume":"180","author":"Salhi","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0100","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2014.05.016","article-title":"In situ cytokines (IL-4, IL-10, IL-12, IFN-gamma) and chemokines (MCP-1, MIP-1alpha) gene expression in human Leishmania (Leishmania) Mexicana infection","volume":"69","author":"Valencia-Pacheco","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2016.06.004_b0105","first-page":"69","article-title":"CD40\/CD40 ligand interactions in immune responses and pulmonary immunity","volume":"73","author":"Kawabe","year":"2011","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.cellimm.2016.06.004_b0110","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1073\/pnas.83.12.4494","article-title":"Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50","volume":"83","author":"Clark","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellimm.2016.06.004_b0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4049\/jimmunol.147.1.8","article-title":"Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways","volume":"147","author":"Gascan","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyad","volume":"58","author":"Schonbeck","year":"2001","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cellimm.2016.06.004_b0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.it.2011.10.004","article-title":"TNF superfamily in inflammatory disease: translating basic insights","volume":"33","author":"Croft","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0130","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/eji.1830250639","article-title":"A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation","volume":"25","author":"Graf","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0135","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.4049\/jimmunol.164.11.5858","article-title":"IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40\/CD40 ligand-dependent process","volume":"164","author":"Marovich","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1074-7613(00)80436-7","article-title":"CD40 ligand is required for protective cell-mediated immunity to Leishmania major","volume":"4","author":"Campbell","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2016.06.004_b0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1074-7613(00)80435-5","article-title":"Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity","volume":"4","author":"Kamanaka","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2016.06.004_b0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1074-7613(00)80434-3","article-title":"Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection","volume":"4","author":"Soong","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2016.06.004_b0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1006\/cimm.1998.1267","article-title":"Underproduction of interleukin-12 in susceptible mice during progressive leishmaniasis is due to decreased CD40 activity","volume":"184","author":"Heinzel","year":"1998","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1128\/IAI.69.2.665-672.2001","article-title":"Influence of costimulatory molecules on immune response to Leishmania major by human cells in vitro","volume":"69","author":"Brodskyn","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cellimm.2016.06.004_b0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<525::AID-IMMU525>3.0.CO;2-M","article-title":"The induction of a protective response in Leishmania major-infected BALB\/c mice with anti-CD40 mAb","volume":"28","author":"Ferlin","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0170","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1128\/IAI.71.3.1389-1395.2003","article-title":"CD40-CD40 ligand costimulation is not required for initiation and maintenance of a Th1-type response to Leishmania major infection","volume":"71","author":"Padigel","year":"2003","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cellimm.2016.06.004_b0175","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.4049\/jimmunol.167.10.5874","article-title":"The development of a Th1-type response and resistance to Leishmania major infection in the absence of CD40-CD40L costimulation","volume":"167","author":"Padigel","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0180","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.micinf.2004.09.015","article-title":"Role of costimulatory molecules in immune response of patients with cutaneous leishmaniasis","volume":"7","author":"Favali","year":"2005","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cellimm.2016.06.004_b0185","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.4049\/jimmunol.1500922","article-title":"Interaction of macrophage antigen 1 and CD40 ligand leads to IL-12 production and resistance in CD40-deficient mice infected with Leishmania major","volume":"195","author":"Okwor","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1074-7613(00)80455-0","article-title":"LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator","volume":"8","author":"Mauri","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2016.06.004_b0195","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1172\/JCI3492","article-title":"LIGHT, a novel ligand for lymphotoxin beta receptor and TR2\/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer","volume":"102","author":"Zhai","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2016.06.004_b0200","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.4049\/jimmunol.164.8.4105","article-title":"LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response","volume":"164","author":"Tamada","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0205","doi-asserted-by":"crossref","first-page":"27548","DOI":"10.1074\/jbc.273.42.27548","article-title":"Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM\/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth","volume":"273","author":"Harrop","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2016.06.004_b0210","doi-asserted-by":"crossref","first-page":"13733","DOI":"10.1074\/jbc.274.20.13733","article-title":"A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis","volume":"274","author":"Yu","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2016.06.004_b0215","doi-asserted-by":"crossref","first-page":"14272","DOI":"10.1074\/jbc.272.22.14272","article-title":"A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation","volume":"272","author":"Kwon","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2016.06.004_b0220","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.165.8.4397","article-title":"Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor","volume":"165","author":"Morel","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0225","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nri1151","article-title":"Lymphotoxin\/light, lymphoid microenvironments and autoimmune disease","volume":"3","author":"Gommerman","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0230","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.4049\/jimmunol.175.10.6997","article-title":"Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion","volume":"175","author":"Wang","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0235","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/73136","article-title":"Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway","volume":"6","author":"Tamada","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellimm.2016.06.004_b0240","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.4049\/jimmunol.167.11.6330","article-title":"Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction","volume":"167","author":"Shaikh","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0245","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI200113827","article-title":"The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT","volume":"108","author":"Wang","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2016.06.004_b0250","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.4049\/jimmunol.179.8.5358","article-title":"Lymphotoxin alpha beta 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice","volume":"179","author":"Xu","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0255","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.4049\/jimmunol.179.10.6901","article-title":"LIGHT Is critical for IL-12 production by dendritic cells, optimal CD4+ Th1 cell response, and resistance to Leishmania major","volume":"179","author":"Xu","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002279","article-title":"Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection","volume":"7","author":"Stanley","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cellimm.2016.06.004_b0265","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4049\/jimmunol.1401892","article-title":"Deficiency of CD40 reveals an important role for LIGHT in anti-Leishmania immunity","volume":"195","author":"Okwor","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0270","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1385\/IR:25:3:219","article-title":"Role of the lectin domain of Mac-1\/CR3 (CD11b\/CD18) in regulating intercellular adhesion","volume":"25","author":"Ross","year":"2002","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cellimm.2016.06.004_b0275","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.106.683201","article-title":"CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1","volume":"115","author":"Zirlik","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cellimm.2016.06.004_b0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00919970","article-title":"CR3 (CD11b\/CD18) expressed by cytotoxic T cells and natural killer cells is upregulated in a manner similar to neutrophil CR3 following stimulation with various activating agents","volume":"13","author":"Muto","year":"1993","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0285","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.4049\/jimmunol.135.4.2785","article-title":"The mouse macrophage receptor for C3bi (CR3) is a major mechanism in the phagocytosis of Leishmania promastigotes","volume":"135","author":"Mosser","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0290","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.4049\/jimmunol.144.12.4817","article-title":"Lipophosphoglycan from Leishmania mexicana promastigotes binds to members of the CR3, p150,95 and LFA-1 family of leukocyte integrins","volume":"144","author":"Talamas-Rohana","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0295","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1128\/IAI.00802-08","article-title":"Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB\/c mice","volume":"77","author":"Carter","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cellimm.2016.06.004_b0300","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.4049\/jimmunol.171.10.5437","article-title":"TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice","volume":"171","author":"Padigel","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.06.004_b0305","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/1471-2334-13-331","article-title":"High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis","volume":"13","author":"de Oliveira","year":"2013","journal-title":"BMC Infect. Dis."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874916300491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874916300491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:55:35Z","timestamp":1757804135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874916300491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":61,"alternative-id":["S0008874916300491"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2016.06.004","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2016.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}